Healius Limited (FRA:PGZ)

Market Cap	405.66M
Revenue (ttm)	750.40M
Net Income (ttm)	-84.41M
Shares Out	n/a
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	49.53
Dividend	0.24 (43.93%)
Ex-Dividend Date	May 9, 2025

Volume	n/a
Average Volume	10
Open	0.5350
Previous Close	0.5750
Day's Range	0.5350 - 0.5350
52-Week Range	0.3780 - 0.9100
Beta	n/a
RSI	55.74
Earnings Date	Nov 19, 2025

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Offices and Clinics of Doctors of Medicine
• Founded: 1994
• Employees: 8,224
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PGZ

Financial Performance

In 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.

Financial numbers in AUD